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osting by EAbstract Aim: To evaluate the knowledge of health professionals in Palestine regarding the
advantages of sustained release dosage forms (SRDFs) over conventional therapy.
Methods: Data were gathered from a questionnaire that was handed out to community pharma-
cists, physicians and patients. Pharmaceutical industry decision makers were enrolled in this study.
Data were analyzed using the SPSS.
Results: Pharmacists (92.9%) and 89.2% of physicians thought that SRDFs improve patient com-
pliance. 81.5% of pharmacists and 77% of physicians were in agreement regarding the capacity of
SRDFs to maintain therapeutic activity during night. In this study, 81.5% of pharmacists and 81%
of physicians believed that SRDFs provide further advantage with psychiatric patients who forget
to take their medications. Pharmacists (63.1%) and only 63.5% of physicians believed that SRDFs
yield a time saving for nurses who use SRDFs in hospital. Only 45.3% of physicians and 43.4% of
pharmacists thought that SRDFs result in cost saving due to better disease management. Pharma-
cists (95.2%) and 95.9% of physicians agreed that SRDFs could be the right choice for faith
patient’s who must take their medication during the month of Ramadan. Pharmacists (66.7%)
and 50.7% of physicians recognize that SRDFs may be unsafe if they are improperly formulated.
Bad swallowing was also recognized as inconveniences of SRDFs by 67.9% of pharmacists and
57.3% of physicians. Given the above advantages, 75% of patients showed economical problems
regarding the cost of the single course therapy of SRDFs and 100% of interviewed patients were
enthusiastic about the advantage of SRDFs during Ramadan.5982.
aid_n52@hotmail.com
ity. All rights reserved. Peer-
d University.
lsevier
252 A.N. ZaidConclusion: The advantages of SRDFs are not completely understood by Palestinian health profes-
sionals. Pharmaceutical industries should pay more attention to the development and advertising of
SRDFs due to the valuable advantages of these dosage forms.
ª 2010 King Saud University. All rights reserved.1. Introduction
Drugs are often administered on scheduled bases to maintain
the therapeutic level of pharmaceutical active ingredient in
plasma or tissue in order to obtain a constant therapeutic ef-
fect over an extended period of time. This can be achieved
with different dose and dosing interval. From the point of
view of patient compliance, however the dosage regimen of
orally administered drug may be considered to be optimal
when the therapeutic effect is maintained for the desired
duration of treatment at the lowest frequency of administra-
tion (de Haan and Lerk, 1983; Allen et al., 2005). This last
desire can be achieved by using oral sustained release dosage
forms (SRDFs) such as tablets and capsules. In fact, these
dosage forms are commonly administered only once or twice
daily, compared to the counterpart immediate release dosage
forms (IRDFs) that have to be taken three or four times
daily to achieve the same therapeutic effect. Typically,
SRDFs provide immediate release of a portion of the drug
that promptly produces the desired therapeutic effect, fol-
lowed by gradual release of additional amounts of drug to
maintain its therapeutic effect over a predetermined period.
Consequently this optimizes the biopharmaceutic, pharmaco-
kinetic and pharmacodynamic properties of the drug in such
a way that its utility is maximized through reduction in side
effects and control of condition in the shortest possible time
(Stepenskya et al., 2001). These fascinating dosage forms
have gained further importance and so they have been
increasingly used in the last decades. In fact, SRDFs medi-
cations offer many clinical and convenience advantages for
patients as compared to immediate-release IRDFs. Among
these:
(i) Improving patient compliance, since usually only one
tablet has to be taken daily (Genton, 2005; Hale et al.,
2007; Van Assche et al., 1990).
(ii) Maintaining therapeutic activity during night (Aulton,
2007).
(iii) Time saving for nurses who use SRDFs in hospital (Aul-
ton, 2007).
(iv) Providing further advantage with psychiatric patients
who forget to take their medications (Keith, 2006).
(v) Cost saving due to better disease management (Ward
et al., 2007; Sinha et al., 2009; Das and Das, 2003).
(vi) SRDFs are the right choice for faithful patients or Mus-
lims who must take their medication during the month
of Ramadan (a month of fasting, is a daily abstinence
from any food, beverage, or oral drug from dawn to
sunset).
Unfortunately, only drugs that have the appropriate phys-
ico-chemical characteristics (based on suitable biological half-
lives or/and drugs that requires speciﬁc requirements for their
oral absorption) are candidates for sustained release formula-tions (Ramteke et al., 2006). Factors such as unsafety, due to
over dosage, if SRDF is improperly formulated and improper
swallowing, due to the large size of SRDFs, were the main
problems of these dosage forms (Cornish, 2005; Andersen
et al., 1995; Overgaard et al., 2001; Wamberg, 1988; Hey
et al., 1983).
Despite these problems the improvement in patient compli-
ance for long-term therapy encouraged many pharmaceutical
companies to develop SRDFs for many pharmaceutically ac-
tive ingredients. In fact, in the past recent years, there have
been several ﬁnancially successful passive SRDFs including
those of carbamazipina, clarithromycin, verapamil, ciproﬂoxa-
cin, clonidine and tramadol. This commercial success has gen-
erated further interest to expand the scope of therapeutics for
the oral sustained release. In the light of what was mentioned
above regarding these dosage forms, we decided to evaluate
the attitudes of Palestinian health professionals and their
assessment toward the advantages and disadvantages of
SRDFs in the pharmaceutical ﬁeld.2. Materials and methods
This study was based on a questionnaire that was composed
of three sections. The ﬁrst part was a table where health pro-
fessionals were asked to ﬁll in details with trade names of
oral SRDFs present in the Palestinian market, their manu-
facturing companies and the active ingredients contained
therein. The second part was composed of another question-
naire which was ﬁlled by patients who were asked to com-
ment about the following two statements: (i) the cost of
SRDFs and (ii) the administration of medication during
Ramadan. The third part was also a table where the health
professionals were asked to comment on a statement regard-
ing the advantages of SRDFs such as improving patient
compliance, giving controlled release, maintaining therapeu-
tic activity during night, time saving of hospital nurses, pro-
viding further advantages with psychiatric patients who
forget to take their medications. Cost saving due to better
disease management and being the best alternative to con-
ventional IRDFs during Ramadan for faith Muslims or
other faiths including Judaism and Hinduism were consid-
ered additional advantages of these dosage forms. Health
professionals were also asked about the disadvantages of
SRDFs, such as irritation and sensitization, and the limita-
tion of this therapeutic system to only those drugs with
appropriate physico-chemical properties. The questionnaire
was handed out during the period of November 10th through
December 10th, 2009. The questionnaire was distributed to
both physicians and community pharmacists by the fourth
year pharmacy students of An-Najah University. After col-
lection of the ﬁlled forms, the data were entered and descrip-
tively analyzed using statistical software program version
(SPSS 16), (SPSS Inc., Chicago, IL, USA).
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3.1. Physicians’ and pharmacists’ attitudes
The questionnaire was distributed throughout the cities of the
west bank where it was ﬁlled by 148 physicians and 168 com-
munity pharmacists. Pharmacists were also asked to write the
name of SRDFs available in their pharmacy. In addition, 16
decision makers also responded by ﬁlling the speciﬁed part
of the questionnaire. Only fourteen (14) different trade names
were found in the Palestinian market, three of which were car-
bamazepine-sustained release, while the remaining SRDFs
were represented by one active ingredient for each trade name.
Only three of these SRDFs were produced in Palestine, one of
which (Tramal Long) was produced by Pharmacare under the
license of Grunenthal GmbH (Table 1).
Among the participant, 92.9% of pharmacists and 89.2%
of the physicians reported that SRDFs improve patient com-
pliance. The results obtained also showed that the majority
of community pharmacists (81.5%) and most physicians
(77%) were in agreement regarding the capacity of SRDFs
to maintain therapeutic activity of the drug during night
(Table 2). In this study, equal percentages of the physicians
and pharmacists (81.5% and 81%) agreed that SRDFs may
provide further advantage with psychiatric patients who usu-
ally forget to take their medications. This also results in
improvement of patient compliance better than the corre-
sponding counterpart IRDFs that may have to be adminis-
tered three or four times daily to achieve the same
therapeutic response (Table 2). Most of the community phar-
macists (63.1%) and physicians (63.5%) believed that the use
of SRDFs results in time saving for nurses (Table 2). AlmostTable 1 Sustained release dosage forms available in the
Palestinian pharmaceutical market.
Trade name Pharmaceutical
active ingredient
Manufacturer
Klacid XL Clarithromycin Abbot
Efexor XR Venlafaxine Wyeth
Adizem CD Diltiazem HCl Rafa
Delatam Diltiazem HCl Abic
Anafranil Clomipramine Novartis
Lescol XL Fluvastatin Novartis
Etopan XL Etodolac Taro
Tramal Tramadol HCl Pharmacare, under
license of Grunenthal
Decongex SR Chlorpheniramine Maleate
and pseudoephedrine HCl
Belpharm
Gripmin SR Pseudoephedrine HCl Jerusalem
Omnic Tamsulosine Astellas Pharma
Omnic-Ocas Tamsulosine Asttelas Pharma
Trental Pentoxyfyllin Aventis
Timonil Carbamazepine Megapharm
Teril Carbamazepine Taro
Tegretol CR Carbamazipine Novartis
Osmo-Adalat Nifedipine Perrigo (Agis)
Xatral SR Alfuzosine Sanoﬁ Aventis
Depalept Chrono Sodium valproate
and valproic acid
CTS
Ikapress SR Verapamil Teva
Pentasa Mesalamine Fairinga minority of pharmacists and physicians (43.4% and
45.3%), respectively had the same opinions regarding the cost
saving due to better management of the disease when SRDFs
are used instead of other oral IRDFs containing the same
pharmaceutically active ingredients. With respect to the state-
ment of ‘‘SRDFs could be the right choice for faith patients
who must take their medication during the month of Ramadan
without stopping their fasting’’. About the absolute majority
of physicians and community pharmacists who participated
recognized that SRDFs are the right choice for these faith pa-
tients (Table 2). On the other hand, most pharmacists (66.7%)
and about one half of physicians (50.7%) recognized that the
main limitation of SRDFs is their unsafety if they are improp-
erly formulated (Table 2). Regarding the large size of some
SRDFs which may result in difﬁculty swallowing, 67.9% of
pharmacists and 57.3% of physician agreed.
3.2. Patients viewpoint
This part of study was composed of only two statements. The
ﬁrst one discussed the higher cost of the single course therapy
of SRDFs in comparison with IRDfs containing the same ac-
tive ingredients and how this cost can be overcome by better
disease management and less side effects. Here, the majority
of patients (75%) understood and were agreed with this discus-
sion. The second statement discussed the advantage of SRDFs
during Ramadan, since they can take these medications orally
and so patients can adhere to fasting. Here one hundred per-
cent of interviewed patients were enthusiastic to hear about
such pharmaceutical innovation.
3.3. Industrial personnel viewpoints
Table 3 shows industrial personnel questionnaire in which they
were asked to pick the reasons pharmaceutical companies have
developed very small number of SRDFs. One half of inter-
viewed pharmaceutical decision makers thought that the rea-
son behind the scarce or non-development of these dosage
forms was lack of technology or specialized personnel to devel-
op SRDFs. A high percentage of the questioned personnel
(71.4%) believed that poor development of SRDFs may be
due to either strategic company decisions or to the high cost
of production. Only 7.14% of the interviewed decision makers
believed that bad understanding of health professionals
regarding the importance of SRDFs in the therapeutic ﬁeld re-
lies on the strategy of non-developing SRDFs.
4. Discussion
The number of SRDFs formulations found in the Palestinian
market shows that this therapeutic system is poorly available
in this country. The majority of the participating pharmacists
and physicians had nearly positive opinions about what was
expected regarding the advantages and disadvantages of
SRDFs but they still need to improve their knowledge on some
other points mentioned in this study. But the result of this
study should encourage the increase in the number of these
formulations in the Palestinian pharmaceutical market and
thus improve the efﬁcacy of the therapeutic drug treatment
considering the previously mentioned advantages which play
a fundamental role in the improvement of drug compliance.
Table 2 Comments of physicians and pharmacists regarding the advantages and disadvantages of SRDFs.
Statements asked to physicians and pharmacists
regarding the characteristics of TTS
Pharmacists Physicians
Agree (%) Disagree (%) Uncertain (%) Agree (%) Disagree (%) Uncertain (%)
SRDFs improve patient compliance, since only one
tablet has to be taken daily
92.9 5.4 1.7 89.2 6.1 4.7
SRDFs maintain therapeutic activity during night 81.5 14.3 4.2 77 14.9 8.1
SRDFs provide advantages with psychiatric patients
who usually forget or refuse to take their medications
81.5 13.7 4.8 81 12.2 6.8
Time saving for nurses hospital due to the use of
SRDFs
63.1 18.5 18.5 63.5 20.9 15.5
Cost saving due to better disease management when
SRDFs are used
43.4 31.0 25.6 45.3 37.8 16.9
SRDFs could be the right choice for faith patient’s
who take their medication during the month of
Ramadan
95.2 1.8 2.4 95.9 1.4 2.7
Unsafety due to over dosage if SRDF is improperly
formulated
66.7 17.3 16.1 50.7 44.6 4.7
Bad swallowing due to the large size of SRDFs 67.9 22 10.1 57.3 32.5 10.2
Table 3 The comments of industrial personnel regarding the
reasons of the poor development of SRDFs.
Statements asked to industrial
personnel regarding the reason
of not developing
chewable tablets
Agree
(%)
Disagree
(%)
Uncertain
(%)
Very costly 71.4 21.4 7.2
SRDFs are not fully evaluated
and accepted by
physicians and pharmacists
7.1 42.9 50
Lack of technology or
specialized personnel
50.0 42.9 7.1
The company has more
important strategies
71.4 28.6 0.0
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SRDFs compared with immediate release formulations, con-
taining the same pharmaceutically active ingredient, is a very
important factor in the selection of the treatment. In fact,
SRDFs play an important role in this contest, since these dos-
age forms maintain their therapeutic activity during night and
this will avoid the awakening of patients during night to take
their medication. At the same time, a further advantage is
achieved when SRDFs are used in the ﬁeld of psychiatric pa-
tients who usually forget or refuse to take their medication
as reported by the majority of interviewed physicians and
pharmacists. With this advantage, it is expected that a prefer-
ential attitude toward these dosage forms is practiced when
supplying certain medications in psychiatric clinics.
Another very important result to be discussed is the cost
saving due to time saving of nurses who use SRDFs in hospi-
tals where most of pharmacists (63.1%) and physicians
(63.5%) agreed with this issue. These results should be dis-
cussed carefully since, knowing that time saving to nurses in
the hospitals should be achieved when SRDFs are used. This
may result in a decrease in the number of employed nurses
which return in cost saving for hospitals who use these dosage
forms. This point should not be isolated in terms of cost from
the obtained results regarding the cost saving due to bettermanagement of therapy when SRDFs are used. Here unfortu-
nately, a small number of both pharmacists and physicians
agreed with this point. Probably these results can be inter-
preted when pharmacists and physician consider the cost of
the single course therapy, which is usually higher than the cor-
responding IRDFs. As the better disease management was im-
proved due to avoidance of drug plasma ﬂuctuation and
minor probabilities of forgetting the dose administration,
these factors associated with the discussed higher patient com-
pliance should result in better disease management and so cost
saving for patient and society alike. Concerning the use of
SRDFs during Ramadan, about the absolute majority of
interviewed pharmacists and physicians consider SRDFs as
an ideal choice for those patients who refuse to stop fasting
(in Ramadan) if they have to take their medication during
day. This clearly results in worsening of their medical condi-
tions. But once again the use of the corresponding SRDFs
should be an ideal alternative since patients are able to take
their dose after the sunset. This important result will clearly re-
turn in high economic outcome for pharmaceutical industries
that produce SRDFs considering that Islam is the world’s sec-
ond largest religion and has 1.57 billion adherents, making up
23% of the world population (Miller, 2009). According to
these ﬁndings, we recommend pharmacists and physicians to
pay more attention to SRDFs and to talk with patients about
these advantages in order to convince them to shift their ther-
apy from IRDFs toward SRDFs. In fact, this will be impor-
tant for pharmacists and physicians since the high patient
compliance achieved from SRDFs will improve the trust be-
tween patients and caregivers which means again higher med-
ical beneﬁts. Again the results obtained from the interviewed
patients should encourage doctors and pharmacists to push
in such direction, since the majority of patients do not have
problem with the higher cost of the single course therapy. In
fact these patients accepted the idea of overcoming and cost
saving due to better disease management and less side effects
when they use SRDFs instead of IRDfs. Further encourage-
ment was obtained from the enthusiasm that was showed by
the interviewed patients regarding SRDFs and Ramadan. In
fact, these patients expressed their satisfaction to hear about
such formulation and they said that in future they will ask
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especially during Ramadan. Regarding the results related to
the unsafety of SRDFs if these are improperly formulated,
most pharmacists and physicians agreed with this. In fact,
SRDFs may produce accidental toxicity which is difﬁcult to
be treated if these formulations accidentally release their total
content of pharmaceutically active ingredient. Regarding the
results related to the large size of some SRDFs and the effect
of this issue on the improper swallowing, most pharmacists
and physicians agreed with this point. In fact, administration
of oral dosage forms to children presents a challenge for both
health professionals and patients equally. Also for many
adults, it is not always easy to swallow drugs in the form of
tablets. In fact, a study performed in Norway showed that
every third woman and every sixth man agreed to have prob-
lems with swallowing tablets (Cornish, 2005; Andersen et al.,
1995; Overgaard et al., 2001; Wamberg, 1988). Thus, this issue
should be considered seriously by manufacturers in order to
decrease the large size of SRDFs. Regarding the results of
the questionnaire given to decision makers in the pharmaceu-
tical industry, it was interesting to see that this category has
recognized precisely two reasons for the non-development of
SRDFs. In fact, 71.4% of them reported that the high cost
of production is the obstacle. Another obstacle was the strat-
egies of the industries that do not consider SRDFs develop-
ment as an important enterprise. Another obstacle is
represented by the lack of technology or specialized personnel
to develop such dosage form but here only one half of inter-
viewed decision makers recognized this point. However, the
ﬁrst two reasons can be solved by encouraging them to do
investment in the production of SRDFs especially when we
consider the high patient compliance and the use of these dos-
age forms during Ramadan month as was discussed earlier in
this study. Regarding the lack of technology and specialized
personnel, the well-organized scientiﬁc cooperation between
universities and the pharmaceutical industry, as is the case in
many industrial countries, whereby the expertise of university
professors can be of great help in this ﬁeld. Concerning the
second reason, SRDFs are not fully evaluated and accepted
by physicians and pharmacists, this point should not be abso-
lutely a serious problem, since the absolute majority of the
interviewed pharmaceutical decision makers do not agree with
this point. In fact, also the ﬁrst part of this study shows that
the interviewed pharmacists and physicians have a positive
idea about the many advantages of SRDFs. However, a
well-organized labor of medical representatives who must con-
centrate their efforts to educate and inform pharmacists and
physicians about the obvious advantages of such dosage forms
should resolve this issue. Moreover, pharmaceutical compa-
nies should ask and train their medical representative to edu-
cate patients toward the beneﬁts that should be achieved from
using SRDFs, especially regarding the cost of therapy which
as discussed previously may discourage the patient if he thinks
only to the economical part of the course therapy without con-
sidering the great medical beneﬁts that he should achieve. This
is true again when we consider the antibacterial and antiviral
agents. Also, these medical representatives should point the
light on the great advantage and happiness that faith Muslims
patients ﬁned when they know that there is no need any more
to stop their fasting during Ramadan if they use SRDFs in-
stead of IRDFs. In fact, this was seen in the part of study re-
lated to patients viewpoints.5. Conclusions
From the results obtained in the current study, we feel obliged
to recommend some measures that may lead to a better out-
come for the industry and the patient. Firstly, the transforma-
tion of many IRDFs for a number of drugs into SRDFs has
many advantages, such as better compliance and less frequent
administration. The decrease in frequency of administration of
SRDFs is especially important for patients traveling from one
place to another while carrying their medications as well as
saving space, both in industry stores and pharmacy shelves.
Moreover, the use of SRDFs during Ramadan may result in
better disease management and in higher economical outcome
for pharmaceutical industries that produces SRDFs. There-
fore, it is advisable that more attention be given to SRDFs
as an excellent choice for a wide variety of pharmaceutically
active ingredients. Pharmaceutical companies are encouraged
to re-evaluate this issue and to pay more public attention to
it through condensed and scientiﬁc efforts of their medical rep-
resentatives in order to change and improve the knowledge of
many of the pharmacists and physicians who do not possess
the proper information. Also they should aware population
regarding these advantages so patient can ask medical advice
from his physician or pharmacists regarding this issue. This
matter being accomplished will deﬁnitely have a positive effect
on the sales of their marketed products.Acknowledgements
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